← Leaderboards
Brian C. Kraemer
Va Puget Sound Healthcare System
$19,537,143
Attributed
$21,355,260
Total exposure
16
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6M · FY2009–25$10M$7.5M$5M$2.5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$21,355,260 · 10
VA$0 · 6
By mechanism
R01$9,580,757 · 3
RF1$7,178,582 · 3
T32$3,323,269 · 1
R56$573,037 · 1
R21$386,650 · 1
R41$312,965 · 1
Top collaborators
- Elaine R. Peskind5 shared
- Arthur Thomas Suckow2 shared
Most similar at Va Puget Sound Healthcare System
Same institution · by research overlap
- Nicole Faron Liachko$2,745,815
- Patrick Mark Aubin$0
- Sunil V Rao$4,012,769
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposNeuronsNerve DegenerationS DiseaseCaenorhabditis ElegansTauopathiesLesionToxic EffectTau ProteinsPathologyNeurotoxicityDepositionMediatingBrainProteinsMouse ModelGenesDementiaExhibitsFutureMolecularNeuronal DysfunctionTau AggregationPathologic
Grant awards (54)
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's Disease$835,492
T32 · FY2025 · AG
Formation of Tau RNA Complexes disrupts tau function and drives tau neuropathology$661,062
R01 · FY2025 · AG · contact PI
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's Disease$84,354
T32 · FY2025 · AG
Developing MSUT2 Nanobodies for Targeting Pathological Tau in Alzheimer's Disease$0
I01 · FY2025 · VA · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2025 · VA · contact PI
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's Disease$850,926
T32 · FY2024 · AG
Formation of Tau RNA Complexes disrupts tau function and drives tau neuropathology$647,228
R01 · FY2024 · AG · contact PI
Protection from pathological tau by activation of the ER unfolded protein response$567,765
R01 · FY2024 · AG · contact PI
BLRD Research Career Scientist Award Application$0
IK6 · FY2024 · VA · contact PI
Developing MSUT2 Nanobodies for Targeting Pathological Tau in Alzheimer's Disease$0
I01 · FY2024 · VA · contact PI
Targeting MSUT2 with small molecules to ameliorate pathological tau$2,181,250
RF1 · FY2023 · AG · contact PI
SPOP drives neurodegenerative tauopathy$1,823,353
RF1 · FY2023 · AG · contact PI
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's Disease$786,648
T32 · FY2023 · AG
Formation of Tau RNA Complexes disrupts tau function and drives tau neuropathology$638,837
R01 · FY2023 · AG · contact PI
Protection from pathological tau by activation of the ER unfolded protein response$520,000
R01 · FY2023 · AG · contact PI
Developing MSUT2 Nanobodies for Targeting Pathological Tau in Alzheimer's Disease$0
I01 · FY2023 · VA · contact PI
Neurobehavior, Neuropathology, and Risk Factors in Alzheimer's Disease$765,849
T32 · FY2022 · AG
Developing Neuroprotective Strategies for Tau and TDP-43 Proteinopathy in FTLD$549,271
R01 · FY2022 · NS · contact PI
Protection from pathological tau by activation of the ER unfolded protein response$520,000
R01 · FY2022 · AG · contact PI
Developing MSUT2 Nanobodies for Targeting Pathological Tau in Alzheimer's Disease$0
I01 · FY2022 · VA · contact PI
Developing Neuroprotective Strategies for Tau and TDP-43 Proteinopathy in FTLD$538,722
R01 · FY2021 · NS · contact PI
Protection from pathological tau by activation of the ER unfolded protein response$520,000
R01 · FY2021 · AG · contact PI
Reversal of Tau Pathology with MSUT2 siRNA Conjugates$99,938
R41 · FY2021 · AG
Developing Neuroprotective Strategies for Tau and TDP-43 Proteinopathy in FTLD$551,207
R01 · FY2020 · NS · contact PI
Protection from pathological tau by activation of the ER unfolded protein response$530,011
R01 · FY2020 · AG · contact PI
Reversal of Tau Pathology with MSUT2 siRNA Conjugates$213,027
R41 · FY2020 · AG
Inhibiting pathological TDP-43 phosphorylation as a therapeutic strategy for ALS$0
I01 · FY2020 · VA · contact PI
Reversing tauopathy by inhibiting MSUT2 RNA-binding activity$573,037
R56 · FY2019 · AG · contact PI
Developing Neuroprotective Strategies for Tau and TDP-43 Proteinopathy in FTLD$568,671
R01 · FY2019 · NS · contact PI
Inhibiting pathological TDP-43 phosphorylation as a therapeutic strategy for ALS$0
I01 · FY2019 · VA · contact PI
Developing neuroprotective strategies for proteinopathy$295,313
R01 · FY2018 · NS · contact PI
Identifying new tau targeted therapeutics: a drug repurposing approach$0
I01 · FY2018 · VA · contact PI
Inhibiting pathological TDP-43 phosphorylation as a therapeutic strategy for ALS$0
I01 · FY2018 · VA · contact PI
MSUT2 modulates pathological tau in AD and model organisms$3,173,979
RF1 · FY2017 · AG · contact PI
Developing neuroprotective strategies for proteinopathy$295,313
R01 · FY2017 · NS · contact PI
Identifying new tau targeted therapeutics: a drug repurposing approach$0
I01 · FY2017 · VA · contact PI
Inhibiting pathological TDP-43 phosphorylation as a therapeutic strategy for ALS$0
I01 · FY2017 · VA · contact PI
Developing neuroprotective strategies for proteinopathy$295,313
R01 · FY2016 · NS · contact PI
Unfolded protein response activation protects neurons against pathological tau$175,750
R21 · FY2016 · NS · contact PI
Identifying new tau targeted therapeutics: a drug repurposing approach$0
I01 · FY2016 · VA · contact PI
Developing neuroprotective strategies for proteinopathy$295,313
R01 · FY2015 · NS · contact PI
Unfolded protein response activation protects neurons against pathological tau$210,900
R21 · FY2015 · NS · contact PI
Acquisition of a ProteinSimple capillary electrophoresis protein immunoanalyzer$0
IS1 · FY2015 · VA · contact PI
Identifying new tau targeted therapeutics: a drug repurposing approach$0
I01 · FY2015 · VA · contact PI
Developing neuroprotective strategies for proteinopathy$295,313
R01 · FY2014 · NS · contact PI
MSUT2/SUT2 controls tau protein aggregation and neurotoxicity.$0
I01 · FY2014 · VA · contact PI
Developing neuroprotective strategies for proteinopathy: a comparative modeling$252,653
R01 · FY2013 · NS · contact PI
MSUT2/SUT2 controls tau protein aggregation and neurotoxicity.$0
I01 · FY2013 · VA · contact PI
Developing neuroprotective strategies for proteinopathy: a comparative modeling$261,817
R01 · FY2012 · NS · contact PI
MSUT2/SUT2 controls tau protein aggregation and neurotoxicity.$0
I01 · FY2012 · VA · contact PI
Developing neuroprotective strategies for proteinopathy: a comparative modeling$261,817
R01 · FY2011 · NS · contact PI
MSUT2/SUT2 controls tau protein aggregation and neurotoxicity.$0
I01 · FY2011 · VA · contact PI
Developing neuroprotective strategies for proteinopathy: a comparative modeling$260,467
R01 · FY2010 · NS · contact PI
Developing neuroprotective strategies for proteinopathy: a comparative modeling$254,664
R01 · FY2009 · NS · contact PI